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ABSTRACT
Solid tumors are complex ‘‘organs’’ of cancer cells and a
heterogeneous population of hematopoietic cells, mesen-
chymal cells, and endothelial cells. The cancer stem cell
model proposes that tumor growth and progression is
driven by rare populations of cancer stem cells; however,
nontumor-forming stem and progenitor cells are also pres-
ent within the tumor microenvironment. These adult stem
cells do not form tumors when injected into experimental
animals, but they may augment tumor growth through
juxtacrine and paracrine regulation of tumor cells and by
contributing to neovascularization. Thus, cancer cells may
actively co-opt nontumor-forming stem cells distally from
the bone marrow or proximally from nearby tissue and
subvert their abilities to differentiate and maintain tissue
growth, repair, and angiogenesis. This review will cover
the roles of nontumor-forming vascular stem cells in tu-
mor growth and angiogenesis. STEM CELLS 2011;29:163–
168
Disclosure of potential conﬂicts of interest is found at the end of this article.
CANCER STEM CELLS
The suggestion that tumors may be characterized by hierarchies
of organized stem cells was a paradigm shift in our understand-
ing of tumor biology [1]. Putative cancer stem cells (CSCs)
have now been identiﬁed in several tumor types, and several
competing but not necessarily mutually exclusive models have
been put forth to explain tumor cell heterogeneity and propaga-
tion of CSCs. A stochastic model states that all cells within a
tumor have equal abilities to initiate and maintain tumor
growth, whereas a hierarchical model suggests that only a
minor subset of cancer cells can self-renew and give rise to tu-
mor-forming and nontumor-forming progeny. However, the rar-
ity of stem cells in tumors has been brought into question, as has
their existence at all in some mouse tumor models (reviewed in
[2]). Normal stem cells and CSCs can be identiﬁed by efﬂux of
Hoechst dye via multi-drug resistance (MDR) and ATP-binding
cassette transporters [3]. But the ability to export Hoechst dye
diminishes in more committed progeny. By inference, refracto-
riness to chemotherapy could be explained by rapid export of
cytotoxic agents by the CSC pool. Thus, CSC may act as the
‘‘linchpin’’ in some solid tumors and their selective elimination
may initiate a cascade ultimately leading to tumor destruction.
Notably, cancer cells with stem-like properties that express
markers of vascular endothelium and form tumor blood vessels
have been described [4]. However, second populations of
‘‘adult’’ stem/progenitor cells, which do not form tumors, are
also present in the tumor microenvironment and are the build-
ing blocks of most tumor blood vessels. This review covers the
role of this second population of nontumor-forming progenitors
and their role during angiogenesis and tumor progression.
DEFINITION OF STEM AND
PROGENITOR CELLS
First, a distinction should be made between bona ﬁde stem
cells that have the capacity for unlimited self-renewal and
multilineage differentiation (e.g., embryonic stem cells) and
progenitor cells or ‘‘precursor cells’’ that have limited self-
renewal and differentiation abilities. The generation of pro-
genitor cells is hierarchical with an undifferentiated parental
cell lying at the apex that generates progressively more differ-
entiated progeny. For example, hematopoietic stem cells,
which reside in the bone marrow, generate an array of more
committed hematopoietic progenitor cells (HPC) that act as
speciﬁc precursors to different blood cell lineages. Mesenchy-
mal stem cells (herein termed mesenchymal progenitor cells
[MPCs]) although often referred to as stem cells, are also a
type of progenitor or ‘‘precursor’’ cell. MPCs are found
throughout the body, they can differentiate to form multiple
cell types (e.g., osteocytes, adipocytes, chondrocytes, ﬁbro-
blasts, and smooth muscle cells) and they have a limited abil-
ity to self-renew. Endothelial progenitor cells (EPCs) are
another type of lineage-restricted progenitor cell. Although
there is still debate about the deﬁnitive site(s) where EPC
reside in the body, the progeny of circulating EPC (deﬁned as
endothelial colony-forming cells [ECFCs]) circulate in
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populations and will form vessel lumens when injected into
mice. EPCs, MPCs, and HPCs are often identiﬁed in blood or
tissues using the markers listed in Table 1.
ENDOTHELIAL PROGENITOR CELLS
EPCs may be deﬁned as circulating precursor cells with the
ability to differentiate to form functional blood vessels at sites
of neovascularization. However, there has been a lack of con-
sensus regarding EPC deﬁnition, origin, and function in
humans and animal models of disease. As a consequence, the
contribution of these cells to the vasculature of solid tumors
is still the subject of lively debate [5].
A seminal article identiﬁed EPC as cells that circulate in
peripheral blood and express markers such as CD34 and vas-
cular endothelial growth factor receptor-2 (VEGF-R2) (kinase
insert domain receptor [KDR]) [6]. However, hematopoietic
cells also express these cellular markers, and they can be
mobilized into circulation from the bone marrow in order to
home to sites of neovascularization. The functional differen-
ces distinguishing hematopoietic cells (generally do not line
blood vessels) from bona ﬁde ECFC (form lumens) are
becoming clear. Yoder et al. suggest that most of the cells
long referred to as EPC are in fact hematopoietic cells that
are proangiogenic and assist during nascent vessel formation
but have no ability to form vessel lumens (reviewed in [7]).
The discrepancies surrounding the deﬁnition of EPC have
made it difﬁcult to identify these elusive cells in vivo, espe-
cially in tumors. Bone marrow has been proposed as a depot for
circulating EPC in humans and in mouse tumor models
although it is not always clear whether the identiﬁed cells are
ECFC or hematopoietic cells located close to the blood vessel
wall (reviewed in [8]). The absolute number of putative bone
marrow EPC is suggested to differ dramatically depending on
the tumor site, mouse strain, stage of tumor progression, and
method of quantiﬁcation (reviewed in [9]). Gao et al. [10] sug-
gest that EPC facilitate metastasis as their genetic ablation
using ID1 shRNA mitigated pulmonary micro metastasis and
impaired angiogenesis. Some chemotherapies are reported to
increase EPC in circulation and their homing to tumors
following vascular damage [11]. On the other hand, some stud-
ies report minimal contribution of EPC to the tumor vasculature
and question the importance of these cells during tumor growth
[12] (for further discussion see [13]). Our lab recently showed
that the endothelium in spontaneous prostate tumors was rarely,
if ever, derived from the bone marrow and instead most likely
recruited from nearby tissue [14]. Interestingly, we also found
no difference in the number of incorporated circulating endo-
thelial cells in prostate tumors versus normal age-matched pros-
tates. Studies in humans using sex-mismatched bone marrow
transplants also suggest a minor but steady-state incorporation
of donor-derived endothelium in normal tissues at levels similar
to those reported in human cancers [15].
Recently, the vascular wall itself has been proposed as a
source for EPC because it contains subpopulations of
Table 1. Common markers used to identify EPC, MPC, HSC, and HPC
Cell type Human Mouse
EPC (Alternative terminology:
ECFC, OEC)
Positive expression EPC are exceedingly rare in mice and are
yet to be isolated and culture expanded.
CD31, vascular endothelial cadherin
(VE-cadherin), vWF, VEGF-R2,
VEGF-R1, CD34, CD146, CD105, eNOS,
UEA-1 lectin (binding), Ac-LDL (uptake)
Negative expression
CD45, CD14, CD11b, CD133,
a CD90
a
MPC (Alternative
terminology: MSC)
Positive expression Positive expression
CD90, CD44, CD29, CD105, NG2,
platelet-derived growth factor (PDGF)-Rb
CD90, CD44, CD29, CD105, NG2, PDGF-Rb
Negative expression Negative expression
CD45, CD14, CD11b, CD31, VE-cadherin CD45, Gr-1, CD11b, CD31, VE-cadherin
HSC Positive expression Positive expression
CD34, CD133 c-Kit, Sca1
Negative expression Negative expression
Lineage-speciﬁc markers Lineage-speciﬁc markers
HPC Positive expression Positive expression
Common antigen Common antigen
CD45 CD45, c-Kit, Sca1
Lineage-speciﬁc markers Lineage-speciﬁc markers
Myeloid: CD11b, CD14, Ac-LDL
(uptake), UEA-1 lectin (binding), CD31,
VEGF-R2, VEGF-R1
Myeloid: CD11b, Gr-1, Ac-LDL
(uptake), BS-1 lectin (binding), CD31,
TIE2, VEGF-R2, VEGF-R1
Lymphoid: CD3, CD4, CD8 Lymphoid: CD3, CD4, CD8
Erythroid: Glycophorin A, Ter-119 Erythroid: Ter-119
Megakaryocytic: CD41, CD42 Megakaryocytic: CD41, CD42
Negative expression Negative expression
CD133 CD133
aCulture-expanded EPC are negative for CD133 and CD90.
Abbreviations: Ac-LDL, acetylated low density lipoprotein; ECFC, endothelial colony-forming cell; eNOS, endothelial nitric oxide synthase;
EPC, endothelial progenitor cell; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; MPC, mesenchymal progenitor cell; OEC,
outgrowth endothelial cells; NG2, chondroitin sulfate proteoglycan; PDGF-Rb, platelet-derived growth factor receptor beta; TIE2, TEK tyrosine
kinase with Ig and EGF homology domains-2; UEA-1, Ulex europaeus agglutinin-1; VE-cadherin, vascular endothelial cadherin; VEGF,
vascular endothelial growth factor; vWF, von Willebrand factor.
164 Vascular Stem Cells and Tumor Angiogenesisendothelial cells with properties similar to blood-derived
ECFC [16]. Because endothelial turnover in resting blood ves-
sels is low, a local and immediate reservoir of highly prolifer-
ative endothelium proximal to the site of injury may be bio-
logically advantageous following tissue injury. Vessel wall
EPC (VW-EPC) are proposed to rest in a ‘‘vasculogenic
zone’’ between the smooth muscle and advential layers at the
periphery of large blood vessels (reviewed in [17]). No stud-
ies to date have determined whether VW-EPC might form the
majority of the angiogenic response in tumors, if there are
any unique properties in VW-EPC that could be exploited as
an antiangiogenesis strategy or if VW-EPC might mediate
vascular rebound following treatment with antiangiogenic
therapies. Deﬁnitive proof for the existence of VW-EPC will
have to wait on the identiﬁcation of a unique marker that can
distinguish these cells from mature vascular endothelial cells.
MESENCHYMAL PROGENITOR CELLS
MPC and their progeny are present in most if not all postnatal
organs. Their major function is to maintain and regenerate
connective tissues and to replenish damaged tissue following
injury or inﬂammation. MPC differentiation is dependent on
the local production of cytokines/growth factors resulting in
tissue speciﬁcity. Therefore, MPC may differentiate into the
type of tissue they engraft [18]. Because paracrine/juxtacrine
interactions between MPC and neighboring cells may be
critical for controlling the rate and timing of differentiation, it
is predicted that crosstalk between mutant cancer cells and
resident MPC could affect their normal differentiation
patterns. A good example is the adipogenic differentiation of
MPC in subcutaneous tumor sites and osteoblastic differentia-
tion at sites of lung metastasis [19]. Similar to HPC, MPC
may be hierarchically organized into heterogeneous clonal
variants with different proliferative and differentiation abil-
ities. Although it has not been investigated, these variants
may function differently depending on tumor stage or type.
MPC may form a large proportion of the reactive stroma in
solid tumors and share properties with carcinoma-activated
ﬁbroblasts, which express alpha smooth muscle actin (a-SMA),
however, it is difﬁcult to distinguish bona ﬁde MPC from ﬁbro-
blasts due to overlapping expression of several surface markers.
Recently, Hoechst dye efﬂux was used to isolate and culture
expand MPC from prostate carcinoma [20]. One unanswered
question is whether bone marrow is the primary source of
MPC in tumors or if there are alternative sites. Factors that typ-
ically stimulate angiogenesis including hypoxia, ischemia, and
proinﬂammatory cytokines also stimulate MPC mobilization;
thus, intravenously delivered MPC display tropism to sites of
injury and engrafted tumors [21]. Notably, marrow-derived
PDGF-Rb
þ progenitor cells were shown to localize in a peri-
vascular position raising the possibility that circulating MPC or
MPC-like cells ‘‘seek out’’ blood vessels in the tissue they
engraft [22]. On the other hand, tumor-associated MPC may be
co-opted from nearby tissue (e.g., adipose tissue) where they
reside in a perivascular niche. For example, Crisan [23] showed
that pericytes and MPC are indistinguishable sharing common
features such as multipotency. Thus, MPC in tumors are con-
veniently positioned to form pericytes, which are major struc-
tural and paracrine cellular components of new blood vessels.
The effect of MPC on primary tumor growth is equivocal
with studies showing enhancement [24], inhibition [25], or no
effect [24] when coinjected with different tumor cell lines.
A recent study showed that neutralization of LL-37, a proin-
ﬂammatory peptide, reduced engraftment of MPC in human
ovarian xenografts resulting in tumor growth inhibition [26].
On the other hand, due to their tumor-homing abilities, MPC
may be exploited as vectors for drug delivery. Studeny et al.
[27] loaded MPC with interferon beta (IFN-b), injected them
intravenously, and found suppression of tumor growth and
metastasis and prolonged survival in mice. Similar to their
effect on primary tumor growth, the role of MPC in metasta-
sis is conﬂicting. Karnoub [24] reported that MPC increased
metastasis when admixed with various tumor cell lines. Other
studies show that intravenous (i.v.) injection of MPC has ei-
ther no effect on 4T1 breast cancer metastasis [19] or reduces
metastasis when MPC are transduced with TRAIL [28]. Some
of these discrepancies are likely due to the different routes of
MPC injection (coinjection with tumor cells vs. i.v. injection).
The tumor-promoting properties of MPC might be related
to angiogenesis stimulation. MPC differentiate to form peri-
cytes and are a major source of VEGF secretion [29].
Although controversial, transdifferentiation of MPC to directly
form endothelium has been reported [30]. Similar to their role
played during wound healing, tumor-associated MPC may
secrete proinﬂammatory chemokines, which recruit proangio-
genic hematopoietic cells (e.g., monocytes and neutrophils)
[31]. On the other hand, one study suggested that MPC dose-
dependently inhibited angiogenesis due to reactive oxygen
species generation, which led to endothelial apoptosis and
vessel regression [32]. Together, MPC and their progeny may
have both protumor and antitumor properties that are tumor-
type dependent or related to the different routes of MPC
injection. Furthermore, MPC might be exploited as drug
delivery vehicles due to their tumor homing properties.
Although laboratory mice are good models for studying the
role of MPC in tumors, their function in clinical cancers has
not been investigated in detail.
HPCS AND THEIR PROGENY
The role of hematopoietic cells in tumor angiogenesis has
recently received great attention. HPC from the bone marrow
emigrate to the blood and tissues and differentiate to form cells
of the innate and adaptive immune system. Tumor-inﬁltrating
leukocytes can either protect against or promote tumor forma-
tion. The simplest example of the former is loss of immune
surveillance and spontaneous tumor formation in some strains
of immunodeﬁcient mice. On the other hand, CD4
þ T lympho-
cytes may promote tumor cell invasion and metastasis by
altering the function of tumor-associated macrophages (TAMs)
[33]. Myeloid lineage cells, including monocytes/macrophages,
neutrophils, dendritic cells, eosinophils, and mast cells feature
prominently in the stroma of most solid tumors (reviewed in
[34]). Although direct stimulation of malignant cells by these
hematopoietic cells is possible, the tumor-promoting abilities of
the recruited myelomonocytic pool is largely related to their
secretion of a variety of proangiogenic factors and ability to
orchestrate the formation of new blood vessels.
One of the ﬁrst clues that HPC might be required for
angiogenesis came from studies in the developing embryo.
For example, acute myeloid leukemia 1 (AML1)–deﬁcient
embryos, which lack deﬁnitive hematopoiesis, showed
impaired angiogenesis in the head and pericardium that was
rescued by addition of HPC-expressing angiopoietin 1 (ANG-
1) [35]. Thus, even physiological angiogenesis is dependent
on crosstalk between the remodeling endothelium and
recruited HPC. Moreover, we showed that ‘‘engineered’’ blood
vessels in the adult mouse are also dependent on
hematopoietic cell recruitment, as selective elimination of
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þ-circulating myeloid cells impaired blood vessel
development and anastomosis with host vasculature [36].
Pathological angiogenesis (e.g., solid tumors) is also charac-
terized by recruitment of an array of myelomonocytic cells
with overlapping phenotypes and functions (reviewed in [37]).
For example, a novel population of proangiogenic TEK tyro-
sine kinase with Ig and EGF homology domains-2 (TIE-2)–
expressing monocytes was recently identiﬁed in tumors [38].
Selective elimination of TIE-2 monocytes impairs tumor
growth and angiogenesis. On the other hand, similar to MPC,
TIE-2 monocytes (and other HPC) may be used as vectors for
drug delivery due to their tumor-homing properties.
The catalytic function of hematopoietic cells during tumor
progression may be related to their expression of proangiogenic
and tissue-remodeling factors including MMPs and VEGF.
Furthermore, tumor-derived factors may activate or change the
phenotype of the recruited pool of hematopoietic cells. A good
example is the M2 skewing of TAMs as tumors become more
vascular and invasive [39]. Macrophages invade most solid
tumors in great numbers and elicit inﬂammatory responses that
are generally protumorigenic and proangiogenic. The numbers
of TAMs in Hodgkin’s lymphoma is associated with a poor
patient prognosis although the factor(s) mediating their tropism
to the tumor site were not identiﬁed [40]. A hypoxia inducible
factor alpha (HIF1a)/chemokine ligand 12 (CXCL-12) axis was
shown to mobilize proangiogenic MMP9-expressing monocytic
cells from bone marrow, which controls a postulated angiogenic
switch in tumors [41]. These marrow-derived monocytic cells
are important mediators of resistance to anti-VEGF therapies
[42] and angiogenesis rebound following radiotherapy [43].
Thus, depletion of speciﬁc populations of HPC and their prog-
eny can have a favorable antitumor response, perhaps by indi-
rectly controlling the rate of angiogenesis.
In addition to their paracrine functions, myeloid-lineage
cells may act as ‘‘vascular bridges’’ by guiding and connect-
ing nascent blood vessels. Proangiogenic TIE-2
þ macro-
phages, for example, were recently shown to guide tip-cell
fusion, a critical step during blood vessel anastomosis [44].
The ability of myeloid-lineage cells to directly form blood
vessels is also possible. Transdifferentiation of CD45
þ mye-
loid cells to form endothelial-like cells was described by
Bailey [45]. Yang et al. [46] found that Gr-1
þ/CD11b
þ cells
acquired properties of endothelial cells in tumors, expressed
VE-cadherin and lined blood vessels. Similarly, lymphatic
vessel endothelial hyaluronan receptor-1 (LYVE-1)
þ macro-
phages were shown to differentiate to form lymphatic endo-
thelium [47], a feature probably related to their inherent plas-
ticity. Taken together, myeloid-lineage cells, through diverse
mechanisms, may facilitate angiogenesis and enable tumor
progression. It will be important to further clarify the factors
mediating trafﬁcking and differentiation of myeloid cells at
the tumor site. The use of ‘‘humanized’’ mice engrafted with
tumor cells could be an important tool for dissecting the func-
tion of HPC and their progeny in the laboratory.
PERSPECTIVE:D O TUMORS SUBVERT
PROGENITOR CELL FUNCTIONS?
Solid tumors are caricatures of a dysfunctional ‘‘organ.’’ In
the shadow of malignant cells is the resident population of
mesenchymal, hematopoietic, and endothelial cells that consti-
tutes the tumor stroma. More than innocent bystanders, these
stromal cells provide a growth advantage, for example, by
forming the building blocks of tumor blood vessels (Fig. 1).
Figure 1. Functions of vascular stem cells in solid tumors. MPC derived from the bone marrow or nearby tissues are a source of VEGF, a
potent endothelial cell survival and motility factor. MPC may also differentiate to form pericytes that provide structural support to the nascent
vasculature. HPC and their progeny act as ‘‘accessory’’ cells during angiogenesis by expressing tissue remodeling and endothelial survival factors
such as MMP9 and VEGF. Similar to MPC, they may provide paracrine instructions to sprouting tip cells during anastomosis. EPC may give rise
to ECFC and constitute the primary lumen-forming cells of angiogenic sprouts. ECFC may also provide unique paracrine cues to neighboring
‘‘adult’’ endothelium or the recruited pool of HPC. Taken together, these three populations of progenitors work in concert to form the building
blocks of tumor blood vessels. ECFC and MPC form lumens and perivascular cells, respectively, whereas HPC direct and orchestrate vessel
sprouting and anastomosis. Abbreviations: EC, endothelial cell; ECFC, endothelial colony-forming cell; EPC, endothelial progenitor cell; HPC,
hematopoietic progenitor cell; MPC, mesenchymal progenitor cell; VEGF, vascular endothelial growth factor.
166 Vascular Stem Cells and Tumor AngiogenesisProlonged paracrine/juxtacrine interactions between malignant
cells and stromal cells might result in unexpected patterns of
differentiation and plasticity, particularly in the resident popu-
lation of more primitive adult stem/progenitor cells. These
subtle changes in the stroma may accelerate or even precede
progression to malignancy.
A clue that malignant cells might impinge on the differen-
tiation state in the stroma comes from studies identifying
aberrant DNA methylation and chromatin modiﬁcation pat-
terns in cancer-associated ﬁbroblasts. Multiple tumor types,
for example, breast and prostate are characterized by stromal
alterations in methylated DNA (reviewed in [48]). Because
normal patterns of differentiation are controlled, in part, by
epigenetic switches, a ‘‘rogue’’ differentiation state of tumor-
associated stromal cells may emerge. For example, we have
shown that prostate tumor endothelial cells have unusual
properties including acquisition of stem-like features and
bipotent differentiation to form bone and cartilage [49]. A
second level of control of stem cell fate and plasticity can
occur through mechanical cues relayed by interactions
between stem cells with the extracellular matrix ECM;
reviewed in [50]). ECM remodeling and stiffening is common
in the stroma of most tumors. For example, the breast tumor
microenvironment is characterized by highly cross-linked col-
lagen that modulates focal adhesions and alters cellular sig-
naling [51]. It will be interesting to determine how changes in
the tumor microenvironment affect the timing and pattern of
differentiation in resident progenitor cells. Furthermore,
whether tumors can ‘‘reprogram’’ the resident pool of progeni-
tor cells, hijacking their normal functions, to facilitate tumor
progression and metastasis should be investigated.
Pathologists have long noted the heterogeneous and disor-
ganized nature of parenchymal cells in tumors. As recently
suggested, these stromal cells may coevolve with tumor cells
during tumor progression and acquire characteristics of tumor
cells nearby [48]. ‘‘Normalizing’’ the tumor microenvironment
to reprogram the fate and plasticity of progenitors within the
stroma, in addition to direct targeting of tumor cells, might be
an effective strategy for reversing or eliminating some
cancers.
CONCLUSION
Solid tumors may be characterized by two populations of
stem/progenitor cells: CSC that may ultimately drive tumor
growth and progression and nontumor/forming progenitors,
some of which comprise the building blocks of tumor blood
vessels. Malignant cells and their supporting stromal cells are
held together by an extracellular matrix. Tumors may thus
resemble dysfunctional organs able to recapitulate features of
development while malignant cells provide corrupt instruc-
tions to surrounding tissues [52]. Understanding how tumors
alter their own microenvironment, in ways that promote their
progression and perhaps ability to metastasize, is critical for
the design of therapies that might eliminate some cancers.
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